No difference was detected in GKN2 levels with respect to clinical parameters, such as age, gender, lymph node metastasis, TNM stage, CEA, NSE, and CYFRA21‐1 (p > 0.999, p = 0.438, p > 0.999, p = 0.299, p = 0.607, p = 0.229, and p = 0.700; Table 2). The gene discussed is CEACAM5; the disease is metastatic malignant neoplasm in the lymph nodes.